Long non‑coding RNAs lnc‑ANGPTL1‑3:3 and lnc‑GJA10‑12:1 present as regulators of sentinel lymph node metastasis in breast cancer

Sun,Desheng; Sun,Desheng; Zhong,Jieyu; Zhong,Jieyu; Wei,Wei; Wei,Wei; Liu,Li; Liu,Li; Liu,Jun; Liu,Jun; Lin,Xiaona; Lin,Xiaona

doi:10.3892/ol.2020.12050

Long non‑coding RNAs lnc‑ANGPTL1‑3:3 and lnc‑GJA10‑12:1 present as regulators of sentinel lymph node metastasis in breast cancer

Authors:
- Desheng Sun
- Jieyu Zhong
- Wei Wei
- Li Liu
- Jun Liu
- Xiaona Lin
View Affiliations

Affiliations: Department of Ultrasonography, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China, Department of Breast Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China, Department of Pathology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China
Published online on: September 3, 2020 https://doi.org/10.3892/ol.2020.12050
Article Number: 188
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNAs (lncRNAs) participate in various biological processed involved in tumorigenesis, metastasis and proliferation. The aim of the present study was to identify candidate long non‑coding RNAs (lncRNAs) involved in sentinel lymph node (SLN) metastasis in breast cancer. Specimens of SLNs were collected from patients with SLN metastasis via punch biopsy. Total RNA was extracted and RNA sequencing (RNA‑seq) was conducted. Differential expression profiles of mRNAs and lncRNAs were obtained via bioinformatics analysis, and Gene Oncology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed on differentially expressed mRNAs. The expression levels of lncRNAs were analyzed via reverse transcription‑quantitative PCR (RT‑qPCR), and the regulation network of the lncRNAs to downstream microRNAs (miRs) and mRNAs was predicted. Based on RNA‑seq results, six differentially expressed candidate lncRNAs were identified in patients with and without SLN metastasis: lnc‑ANGPTL1‑3:3, lnc‑GJA10‑12:1, lnc‑ACAN‑2:1, lnc‑ZPBP2‑4:1, lnc‑GATA3‑16:1 and lnc‑ACOX3‑5:1. KEGG and GO analysis identified that the mitogen‑activated protein kinase (MAPK) and PI3K/Akt signaling pathways were the most enriched pathways. After RT‑qPCR analysis, lnc‑ANGPTL1‑3:3 and lnc‑GJA10‑12:1 exhibited expression patterns that were consistent with those from RNA‑seq. Moreover, receiver operating characteristic curve analysis demonstrated that lnc‑ANGPTL1‑3:3 and lnc‑GJA10‑12:1 expression levels had high sensitivity and specificity in the diagnosis of SLN metastasis, and that their expression levels were upregulated in patients with axillary lymph node metastasis. Further analysis revealed that lnc‑GJA10‑12:1 and lnc‑ANGPTL1‑3:3 were commonly involved in regulating the miR‑302 family, including miR‑302d‑3p and miR‑302c‑3p, which together targeted AKT1. Additionally, lnc‑ANGPTL1‑3:3 was predicted to target miR‑520b to regulate MAP3K2 expression. lnc‑GJA10‑12:1 was also predicted to target miR‑34a‑5p to regulate MAP2K1 and MAP3K9 expression levels, as well as miR‑449a to regulate MAP2K1 expression. The results of the present study suggested that lnc‑ANGPTL1‑3:3 and lnc‑GJA10‑12:1 may potentially serve a role in SLN metastasis of breast cancer by regulating the PI3K/Akt and MAPK signaling pathways via targeting the miR‑302 family, miR‑520a‑3p, miR‑34a‑5p and miR‑449a. Thus, lnc‑ANGPTL1‑3:3 and lnc‑GJA10‑12:1 in SLN may serve as potential markers of breast cancer metastasis.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Choi HY, Park M, Seo M, Song E, Shin SY and Sohn YM: Preoperative axillary lymph node evaluation in breast cancer: Current issues and literature review. Ultrasound Q. 33:6–14. 2017. View Article : Google Scholar : PubMed/NCBI
3	Promish DI: Prediction of axillary lymph node involvement of women with invasive breast carcinoma: A multivariate analysis. Cancer. 85:1201–1203. 1999. View Article : Google Scholar : PubMed/NCBI
4	Fein DA: Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol. 65:34–39. 2015. View Article : Google Scholar
5	Gajdos C, Tartter PI and Bleiweiss IJ: Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg. 230:692–696. 1999. View Article : Google Scholar : PubMed/NCBI
6	Gann PH, Colilla SA, Gapstur SM, Winchester DJ and Winchester DP: Factors associated with axillary lymph node metastasis from breast carcinoma: Descriptive and predictive analyses. Cancer. 86:1511–1519. 2015. View Article : Google Scholar
7	Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM and Osborne MP: Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: Analysis in more than 900 patients. J Am Coll Surg. 191:1–6, Discussion 6–8. 2000. View Article : Google Scholar : PubMed/NCBI
8	Tabár L, Chen HH, Duffy SW, Yen MF, Chiang CF, Dean PB and Smith RA: A novel method for prediction of long-term outcome of women with T1a, T1b, and 10–14 mm invasive breast cancers: A prospective study. Lancet. 355:429–433. 2000. View Article : Google Scholar : PubMed/NCBI
9	Wong JH: Sentinel lymphadenectomy in breast cancer: University research tool or community practice? Surg Clin North Am. 80:1821–1830. 2000. View Article : Google Scholar : PubMed/NCBI
10	Cserni G, Boross G and Baltás B: The role of the histopathological analysis of sentinel lymph nodes in breast cancer. Preliminary findings. Orv Hetil. 139:1899–1903. 1998.(In Hungarian). PubMed/NCBI
11	Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK and Giuliano AE; American College of Surgeons Oncology Group, : Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 25:3657–3663. 2007. View Article : Google Scholar : PubMed/NCBI
12	Veronesi U: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 349:546–553. 2005. View Article : Google Scholar
13	Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, Glass EC and Turner RR: Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 18:2553–2559. 2000. View Article : Google Scholar : PubMed/NCBI
14	Burak WE, Hollenbeck ST, Zervos EE, Hock KL, Kemp LC and Young DC: Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg. 183:23–27. 2002. View Article : Google Scholar : PubMed/NCBI
15	Haid A, Kuehn T, Konstantiniuk P, Köberle-Wührer R, Knauer M, Kreienberg R and Zimmermann G: Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur J Surg Oncol. 28:705–710. 2002. View Article : Google Scholar : PubMed/NCBI
16	Schrenk P, Rieger R, Shamiyeh A and Wayand W: Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 88:608–614. 2000. View Article : Google Scholar : PubMed/NCBI
17	Temple LK, Baron R, Cody HS III, Fey JV, Thaler HT, Borgen PI, Heerdt AS, Montgomery LL, Petrek JA and Van Zee KJ: Sensory morbidity after sentinel lymph node biopsy and axillary dissection: A prospective study of 233 women. Ann Surg Oncol. 9:654–662. 2002. View Article : Google Scholar : PubMed/NCBI
18	Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, et al: lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature. 500:598–602. 2013. View Article : Google Scholar : PubMed/NCBI
19	Huarte M: The emerging role of lncRNAs in cancer. Nat Med. 21:1253–1261. 2015. View Article : Google Scholar : PubMed/NCBI
20	Yan X, Zhang D, Wu W, Wu S, Qian J, Hao Y, Yan F, Zhu P, Wu J, Huang G, et al: Mesenchymal stem cells promote hepatocarcinogenesis via lncRNA-MUF interaction with ANXA2 and miR-34a. Cancer Res. 77:6704–6716. 2017. View Article : Google Scholar : PubMed/NCBI
21	Yin J, Luo W, Zeng X, Zeng L, Li Z, Deng X, Tan X and Hu W: UXT-AS1-induced alternative splicing of UXT is associated with tumor progression in colorectal cancer. Am J Cancer Res. 7:462–472. 2017.PubMed/NCBI
22	Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T and Calin GA: Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 65:1140–1151. 2014. View Article : Google Scholar : PubMed/NCBI
23	Ellinger J, Alam J, Rothenburg J, Deng M, Schmidt D, Syring I, Miersch H, Perner S and Müller SC: The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. Am J Cancer Res. 5:27992015.PubMed/NCBI
24	Shi J, Li X, Zhang F, Zhang C, Guan Q, Cao X, Zhu W, Zhang X, Cheng Y, Ou K, et al: Circulating lncRNAs associated with occurrence of colorectal cancer progression. Am J Cancer Res. 5:2258–2265. 2015.PubMed/NCBI
25	Zhang K, Shi H, Xi H, Wu X, Cui J, Gao Y, Liang W, Hu C, Liu Y, Li J, et al: Genome-wide lncRNA microarray profiling identifies novel circulating lncRNAs for detection of gastric cancer. Theranostics. 7:213–227. 2017. View Article : Google Scholar : PubMed/NCBI
26	Shen X, Bai Y, Luo B and Zhou X: Upregulation of lncRNA BANCR associated with the lymph node metastasis and poor prognosis in colorectal cancer. Biol Res. 50:322017. View Article : Google Scholar : PubMed/NCBI
27	Kong Q and Qiu M: Long noncoding RNA SNHG15 promotes human breast cancer proliferation, migration and invasion by sponging miR-211-3p. Biochem Biophys Res Commun. 495:1594–1600. 2018. View Article : Google Scholar : PubMed/NCBI
28	Pan Y, Pan Y, Cheng Y, Yang F, Yao Z and Wang O: Knockdown of LncRNA MAPT-AS1 inhibites proliferation and migration and sensitizes cancer cells to paclitaxel by regulating MAPT expression in ER-negative breast cancers. Cell Biosci. 8:72018. View Article : Google Scholar : PubMed/NCBI
29	Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, et al: Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 67:472–492. 2017. View Article : Google Scholar : PubMed/NCBI
30	Wang X, Liu J, Zhou G, Guo J, Yan H, Niu Y, Li Y, Yuan C, Geng R, Lan X, et al: Whole-genome sequencing of eight goat populations for the detection of selection signatures underlying production and adaptive traits. Sci Rep. 6:389322016. View Article : Google Scholar : PubMed/NCBI
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
32	Sui J, Li YH, Zhang YQ, Li CY, Shen X, Yao WZ, Peng H, Hong WW, Yin LH, Pu YP and Liang GY: Integrated analysis of long non-coding RNA-associated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma. Int J Oncol. 49:2023–2036. 2016. View Article : Google Scholar : PubMed/NCBI
33	Yan Q, Jiang L, Liu M, Yu D, Zhang Y, Li Y, Fang S, Li Y, Zhu YH, Yuan YF and Guan XY: ANGPTL1 interacts with integrin α1β1 to suppress HCC angiogenesis and metastasis by inhibiting JAK2/STAT3 signaling. Cancer Res. 77:5831–5845. 2017. View Article : Google Scholar : PubMed/NCBI
34	Söhl G, Nielsen PA, Eiberger J and Willecke K: Expression profiles of the novel human connexin genes hCx30.2, hCx40.1, and hCx62 differ from their putative mouse orthologues. Cell Commun Adhes. 10:27–36. 2003. View Article : Google Scholar : PubMed/NCBI
35	Xiao B, Zhang W, Chen L, Hang J, Wang L, Zhang R, Liao Y, Chen J, Ma Q, Sun Z and Li L: Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor--negative breast cancer based on TCGA data. Gene. 658:28–35. 2018. View Article : Google Scholar : PubMed/NCBI
36	Yang L, Guo Y, Liu X, Wang T, Tong X, Lei K, Wang J, Huang D and Xu Q: The tumor suppressive miR-302c-3p inhibits migration and invasion of hepatocellular carcinoma cells by targeting TRAF4. J Cancer. 9:2693–2701. 2018. View Article : Google Scholar : PubMed/NCBI
37	Cejalvo JM, Pérez-Fidalgo JA, Ribas G, Burgués O, Mongort C, Alonso E, Ibarrola-Villava M, Bermejo B, Martínez MT, Cervantes A and Lluch A: Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer. Breast Cancer Res Treat. 160:69–77. 2016. View Article : Google Scholar : PubMed/NCBI
38	Chin YR and Toker A: The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol Cell. 38:333–344. 2010. View Article : Google Scholar : PubMed/NCBI
39	Liu H, Radisky DC, Nelson CM, Zhang H, Fata JE, Roth RA and Bissell MJ: Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci USA. 103:4134–4139. 2006. View Article : Google Scholar : PubMed/NCBI
40	Li W, Hou JZ, Niu J, Xi ZQ, Ma C, Sun H, Wang CJ, Fang D, Li Q and Xie SQ: Akt1 inhibition promotes breast cancer metastasis through EGFR-mediated beta-catenin nuclear accumulation. Cell Commun Signal. 16:822018. View Article : Google Scholar : PubMed/NCBI
41	Yang XL, Liu KY, Lin FJ, Shi HM and Ou ZL: CCL28 promotes breast cancer growth and metastasis through MAPK-mediated cellular anti-apoptosis and pro-metastasis. Oncol Rep. 38:1393–1401. 2017. View Article : Google Scholar : PubMed/NCBI
42	Wu J, Li WZ, Huang ML, Wei HL, Wang T, Fan J, Li NL and Ling R: Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells. Biochem Biophys Res Commun. 483:10–16. 2017. View Article : Google Scholar : PubMed/NCBI
43	Yu J, Tan Q, Deng B, Fang C, Qi D and Wang R: The microRNA-520a-3p inhibits proliferation, apoptosis and metastasis by targeting MAP3K2 in non-small cell lung cancer. Am J Cancer Res. 5:802–811. 2015.PubMed/NCBI
44	You J, Zhang Y, Li Y, Fang N, Liu B, Zu L and Zhou Q: MiR-449a suppresses cell invasion by inhibiting MAP2K1 in non-small cell lung cancer. Am J Cancer Res. 5:2730–2744. 2015.PubMed/NCBI